Eagle Pharmaceuticals (EGRX) Stock Statistics & Valuation Metrics

Eagle Pharmaceuticals has a market cap or net worth of $29.22M. The enterprise value is ―.

Eagle Pharmaceuticals has 12,986,971 shares outstanding. The number of shares has decreased by -2.65% in one year.

Eagle Pharmaceuticals’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Eagle Pharmaceuticals is ―. Eagle Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Eagle Pharmaceuticals had revenue of 316.61M and earned 35.64M in profits. Earnings per share was 2.76.

In the last 12 months, operating cash flow was -9.32M and capital expenditures -74.00K, giving a free cash flow of -9.39M billion.

Eagle Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Eagle Pharmaceuticals upcoming earnings date is Nov 4, 2024, TBA Not Confirmed.

Eagle Pharmaceuticals as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Eagle Pharmaceuticals has paid 25.79M in taxes.

Eagle Pharmaceuticals EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Eagle Pharmaceuticals has $15.35M in cash and marketable securities with $71.61M in debt, giving a net cash position of $56.26M billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Eagle Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―